In this systematic review and meta-analysis involving 518 patients from 17 published studies, treatment with subthalamic deep brain stimulation for patients with Parkinson disease with LRRK2, GBA, or PRKN gene mutation yielded similar motor outcomes but different changes in dopaminergic doses, activities of daily living, motor complications, and cognitive functions. The gene discussed is PRKN; the disease is Parkinson disease.